Posts
- Beacon 2024 Product Milestones, and a look ahead to 2025.
- Beacon ADC Cited in mAbs Journal
- Beacon ADC Patents: The World’s First Patent Database Developed for Scientists
- Beacon begins its next chapter: new investment from Corten Capital and Ampersand to accelerate life sciences R&D intelligence.
- Beacon Cited in Nature Reviews Drug Discovery
- Beacon Intelligence Expands Beacon Neuroscience with Major Data and Search Enhancements
- Beacon Intelligence Launches Beacon Bispecific Patents to Map Competitor Strategies Earlier
- Beacon Intelligence Launches Beacon Neuroscience to Accelerate CNS Drug Development
- Beacon Intelligence Launches New CVRM Platform
- Beacon Intelligence to accelerate growth in life sciences R&D intelligence with new investment from Corten Capital
- Beacon Launches Immune Tolerance Dataset
- Beacon Launches Oncology Deals and Companies Data Expansion
- Beacon RNA Cited in Nature, NPJ Genomic Medicine
- Introducing Beacon Oncology: The Most Comprehensive Oncology Drug Development Database.
Pages
- About
- Beacon API Whitepaper
- Beacon APIs
- Beacon Consulting
- Beacon Data Analysis & Consulting
- Beacon is for Big Pharma
- Beacon is for Biotechs
- Beacon is for Business Development Teams
- Beacon is for Clinical Development Teams
- Beacon is for Life Science Investors
- Beacon is for Research Teams
- Beacon is for Senior Leadership Teams
- Beacon MCP
- Blogs
- Citations
- Conference Reports
- Contact Us
- Cookie List
- Cookie Policy
- Corporate Relationship Notice
- Events
- Home
- Infographics
- Landscape Reviews
- Market Reports
- Market Research
- News
- Our KOLs
- Privacy Policy
- Resources
- Schedule Beacon Platform Demonstration
- Senior Leadership Team
- Site map
- Takeda Tiered Referral Program
- Terms and Conditions
- Thank You
- Thank You – Beacon Consulting
- Thank You – Beacon CVRM Early Access
- Thank You – Beacon Patents Demo Request
- Thank You – Beacon Referral
- Thank You – Complimentary Trial Request
- Thank You – Webinar Registration
- Thank You For Your Interest
- Thought Leadership
- Tiered Referral Program – Eli Lilly
- Webinars
- Webinars on Demand
- 行业内容下载 – 生物药
Solutions
- Beacon ADC Database
- Beacon Autoimmune Database
- Beacon Bispecific Database
- Beacon Cancer Vaccine Database
- Beacon Cell Therapy Database
- Beacon Checkpoint Database
- Beacon CVRM Database
- Beacon Cytokine
- Beacon DDR Database
- Beacon Gene Therapy Database
- Beacon Microbiome Database
- Beacon Neurology Database
- Beacon Neuroscience Database
- Beacon Oncology Database
- Beacon Oncolytic Viruses Database
- Beacon Psychiatric Database
- Beacon RNA Database
- Beacon TPD Database
Events
- 15th Clinical Biomarkers & CDx Summit Europe 2025
- 16th World ADC London Summit
- 16th World ADC San Diego Summit
- 3rd Cell Therapy for Autoimmune Disease Summit
- 4th Next Generation Gene Therapy Vectors 2025
- 4th World ADC Asia Summit 2025
- 5th Novel Conjugates Summit
- 6th TPD & Induced Proximity Summit Europe
- 7th Targeted Radiopharmaceuticals Summit
- 8th Neuroimmunology Drug Development Summit 2026
- 8th TPD & Induced Proximity Summit
- 8th Treg-Directed Therapies Summit
- 8th TRP Summit Europe
- 9th CAR-TCR Summit Europe
- 9th Neuropsychiatric Drug Development Summit
- ADC Partnering & Investment Summit
- Bio Europe 2026
- Bio Japan 2026
- Neuroscience Innovation Pharma Partnering Summit
- OTS 2026
- PEGS Europe 2026
- T-Cell Engager Therapeutics Summit Europe
- The 10th CAR-TCR Summit
- The 17th World Bispecific Summit
- The 5th Annual mRNA Based Therapeutics Summit
- XDC 2026
Webinars
- AACR 2024: DDR Related Abstracts
- Accelerating Biomarker-Driven Clinical Trials Recruitment in EU Through Innovation & Partnership
- ADC and Immune Checkpoint Combination Therapies
- ADC Fireside Chat – Is a booming landscape a double-edged sword?
- ADC Linker Technology: Advancements & How to Harness Them
- ADCs: New Ways to Achieve Precision Conjugation and Scalable Purification
- Advancing Alzheimer’s Biomarkers: The Role of Brain-derived Circular RNA in Blood-Based Detection and Prediction of Disease Progression
- Allogeneic Cell Therapy Innovations
- Bispecific Antibodies and Immune Checkpoint Modulators
- Bivalent Degrader Landscape
- Building the Evidence for ctDNA as a Surrogate Endpoint in Oncology Drug Development
- Cell Therapy Commercial Research Landscape
- Cell Therapy in 2026: Where the Science, Strategy & Capital Are Moving
- Cytokine Based Drug Development Landscape
- Drug Payload Quantification in LNPs with New Scatter-Free Absorption
- From Subtyping to Measuring and Predicting Outcomes, How AI is Changing Rheumatology and Immunology Research
- Inflammatory Bowel Disease Drug Market Trends
- Liquid Biopsy Landscape: CtDNA in Lung Cancer Research
- Microbiome Targeting Therapeutics in Infectious Disease
- Multi-Payload ADCs: Breakthrough Innovation or Unproven Opportunity? Insights from Beacon’s New Market Report
- Navigating Payload Innovation and Toxicity Trends in ADC Development
- Navigating the Neurological Oligonucleotide Landscape: From Clinical Development to Commercial Opportunity
- Novel Drug Conjugates and Clinical Success: An In-Depth Analysis of Emerging ADCs
- Optimizing Next Generation Viral Vector Safety
- Pioneering New Treatment Options in Relapsed or Refractory Multiple Myeloma with a New Amanitin-based ADC
- Psychiatric Drug Development at an Inflection Point: New Mechanisms, New Technologies, and Hard-Won Lessons from the Clinic
- Review of the Induced Proximity Landscape
- STING TLR Landscape Review
- The ADC Landscape
- The Future of Neuroscience Drug Development: Opportunities and Challenges
- The RNA Gene Therapy Landscape
- The Road Ahead for Addressing Autoimmune Indications with T Cell Therapies
- TPD Disease Landscape
- Unlocking the Future of RNA Therapeutics: Delivery System Evolution, Preclinical Insights, and Market Impact
- Where ADC Innovation Is Going: Multispecific & Multipayload Landscapes Unpacked
Infographics
- 2025 ESMO Highlights: Trends in Oncology
- AACR 2025: A Spotlight on New Drugs
- AACR 2026 Highlights: New Drugs on the Horizon
- ADC Pre-Clinical Development: Where Are We in 2023?
- ADCs in the Oncology Landscape
- ASCO 2023: TPD Landscape Overview
- ASCO 2024: ADC Highlights
- ASCO 2024: Bispecific Highlights
- ASCO 2024: Checkpoint Highlights
- ASCO 2024: Cytokine Highlights
- ASCO 2026 Highlights: Where Oncology is Moving Next
- Cell Therapies for Autoimmune Diseases: The Next Therapeutic Frontier
- Checkpoint Targeting Bispecifics
- Chronic Kidney Disease: Indication Landscape
- DDR Combination Therapies
- Exploring Human Papillomavirus
- Exploring The Synergy Of ADC’s And DDRi’s in Cancer Therapy
- Liquid Biopsy Assays For ctDNA Detection
- Lysosomal Storage Diseases – A Comprehensive Overview
- Microbiome Drug Development in Asia
- Microbiome Drug Development Milestones
- Microbiome Therapeutics and Preclinical Models
- Neoantigen Cancer Vaccines
- Next Generation TPD Degraders
- Next-Gen Therapies: Unlocking the Potential of Bispecific ADCs
- RIMQARTO®:The First Armored CAR T Enters the Market
- SABCS 2025 Highlights: Trends Shaping Breast Cancer Drug Development
- Spatial Biology – The Next Diagnostic Frontier?
- T Cell Engagers: Revolutionizing Autoimmune Disease Treatment
- T-Cell Engager Patents: Commercial Activity and Innovation Insights
- The Adenosine Pathway Clinical Trial Landscape
- The Molecular Glue Landscape
- The mRNA-Based Therapy Landscape
- The Oncology Deals and Companies Landscape
- The Rise of Bispecific Combination Trials
- The Rise of Blood-Brain-Barrier-Enabled Assets
- The Schizophrenia Drug Development Landscape
- Unlocking the Potential of mRNA Cancer Vaccines
Landscape Reviews
- ADC 2024 Landscape Review
- ADC 2025 Landscape Review
- ADC H1 2025 Landscape Review
- ADC H1 2026 Landscape Review
- Autoimmune 2025 Landscape Review
- Autoimmune H1 2025 Landscape Review
- Autoimmune H1 2026 Landscape Review
- Bispecific 2024 Landscape Review
- Bispecific 2025 Landscape Review
- Bispecific H1 2025 Landscape Review
- Bispecific H1 2026 Landscape Review
- Cancer Vaccine 2024 Landscape Review
- Cell Therapy 2024 Landscape Review
- Cell Therapy 2025 Landscape Review
- Cell Therapy H1 2025 Landscape Review
- Cell Therapy H1 2026 Landscape Review
- Checkpoint 2024 Landscape Review
- Cytokine 2024 Landscape Review
- Cytokine 2025 Landscape Review
- Cytokine H1 2025 Landscape Review
- DDR 2024 Landscape Review
- Gene Therapy 2024 Landscape Review
- Gene Therapy 2025 Landscape Review
- Gene Therapy H1 2025 Landscape Review
- Immune Tolerance 2024 Landscape Review
- Microbiome 2024 Landscape Review
- Microbiome 2025 Landscape Review
- Neuroscience 2025 ALS, MS & Epilepsy Landscape Review
- Neuroscience 2025 Landscape Review
- Oncology 2024 Landscape Review
- Oncology 2025 Landscape Review
- Oncology H1 2025 Landscape Review
- Oncology H1 2026 Landscape Review
- Oncolytic Viruses 2024 Landscape Review
- RNA 2024 Landscape Review
- RNA 2025 Landscape Review
- RNA H1 2025 Landscape Review
- RNA H1 2026 Landscape Review
- The Psychiatric Drug Development Landscape
- TPD 2024 Landscape Review
- TPD 2025 Landscape Review
- TPD H1 2025 Landscape Review
- TPD H1 2026 Landscape Review
Conference Reports
- 10th CAR-TCR Post Conference Presentation
- 16th World ADC London Post Conference Presentations
- 16th World ADC San Diego Post Conference Presentation
- 5th Targeted Radiopharmaceuticals Summit US 2026 Presentation
- AACR 2023: ADC Post-Conference Report
- AACR 2023: Bispecific Post-Conference Report
- AACR 2023: Cancer Vaccine Post-Conference Report
- AACR 2023: Checkpoint Post-Conference Report
- AACR 2023: Cytokine Post-Conference Report
- AACR 2023: Oncolytic Viruses Post-Conference Report
- AACR 2024: DDR Post-Conference Report
- AACR 2024: RNA Post-Conference Report
- AACR 2024: TPD Post-Conference Report
- AACR 2025: ADC Pre-Conference Planner
- AACR 2025: Bispecific Post-Conference Report
- AACR 2025: Cell Therapy Post-Conference Report
- AACR 2025: Cytokine Post-Conference Report
- AACR 2025: RNA Pre-Conference Planner
- AACR 2025: TPD Post-Conference Report
- AACR 2026: ADC Post-Conference Report
- AACR 2026: ADC Pre-Conference Planner
- AACR 2026: Bispecific Post-Conference Report
- AACR 2026: TPD Post-Conference Report
- AACR NCI EORTC: DDR Post-Conference Report
- ACR 2025: Autoimmune Post-Conference Report
- ASCO 2023: ADC Post-Conference Report
- ASCO 2023: Bispecific Post-Conference Report
- ASCO 2023: Cancer Vaccine Post-Conference Report
- ASCO 2023: Cell Therapy Post-Conference Report
- ASCO 2023: Checkpoint Post-Conference Report
- ASCO 2023: Cytokine Post-Conference Report
- ASCO 2023: Oncolytic Viruses Post-Conference Report
- ASCO 2023: TPD Post-Conference Report
- ASCO 2024: Cancer Vaccine Post-Conference Report
- ASCO 2024: DDR Post-Conference Report
- ASCO 2024: Oncolytic Viruses Post-Conference Report
- ASCO 2024: TPD Post-Conference Report
- ASCO 2025: Cell Therapy Post-Conference Report
- ASCO 2025: Cytokine Post-Conference Report
- ASCO 2025: TPD Conference Report
- ASCO 2026: ADC Key Highlights
- ASCO 2026: Bispecific Post-Conference Report
- ASCO 2026: TPD Post-Conference Report
- ASGCT 2024: Advanced Therapies Post-Conference Report
- ASGCT 2024: Cell Therapy Post-Conference Report
- ASGCT 2024: Gene Therapy Post-Conference Report
- ASGCT 2025: Cell Therapy Post-Conference Report
- ASGCT 2025: Gene Therapy Post-Conference Report
- ASGCT 2025: RNA Post-Conference Report
- ASGCT 2026: RNA Post-Conference Report
- ASH 2023: Cell Therapy Post-Conference Report
- ASH 2023: Gene Therapy Post-Conference Report
- ASH 2024: ADC Post-Conference Report
- ASH 2024: Cell Therapy Post Conference Report
- ASH 2025: ADC Post-Conference Report
- ASH 2025: Bispecific Post-Conference Report
- ASH 2025: Bispecific Pre-Conference Planner
- ASH 2025: Cell Therapy Post-Conference Report
- ASH 2025: Cytokine Pre-Conference Report
- ASH 2025: TPD Post-Conference Report
- ASH 2025: TPD Pre-Conference Report
- ESMO 2023: Checkpoint Post-Conference Report
- ESMO 2023: Cytokine Post-Conference Report
- ESMO 2023: DDR Post-Conference Report
- ESMO 2026 Congress: Cancer Vaccine Abstracts to Watch
- EULAR 2024: Immune Tolerance Post-Conference Report
- EULAR 2025: Autoimmune Post-Conference Report
- EULAR Congress 2026: Autoimmune Post-Conference Report
- mRNA Summit 2025: Presentation
- SfN 2025 Pre-Conference Planner
- SfN 2025: Neuroscience Post-Conference Report
- SITC 2023: Cancer Vaccine Post-Conference Report
- SITC 2023: Cell Therapy Post-Conference Report
- SITC 2023: Oncolytic Viruses Post-Conference Report
- SITC 2023: RNA Post-Conference Report
- SITC 2024: Bispecific Post-Conference Report
- SITC 2025: Bispecific Post-Conference Report
- SITC 2025: Cell Therapy Post-Conference Report
- SITC 2025: Immuno-Oncology Post-Conference Report
- The Neurological Oligonucleotide Landscape Presentation
- WCLC 2026 Conference Intelligence Report
- World ADC San Diego 2026 Presentation
- World Bispecific & T Cell Engager Summit: Presentation Slides
- World Bispecific Summit 2026 Presentation
Market Reports
- 2024 ADC Insights and Trends
- 2024 Cell Therapy Market Opportunities
- 2024 RNA Insights and Trends
- A Spotlight on the TGF-β Cancer Clinical Trial Landscape
- AAVrh74 Platform Technology Designation Report
- ADC 2024 Q3 Insight Pack
- ADC Manufacturing The Evolving Partnership Between ADC Developers and CDMOs
- ADCs vs. Bispecifics: The Patent Race Redefining Next Generation Biologics
- ADCs: Bridging the East-West Divide
- ADCs: Manufacturing Practices, Challenges & the Road Ahead
- ADCs: The Next Phase of Innovation
- Advanced Therapies at ASGCT 2026: Trends, Signals, and Strategic Insights
- Alzheimer’s Agitation and Psychosis Report
- Approved Checkpoint Drugs in Oncology
- Armored Cell Therapies
- Bispecifics in Autoimmune Disorders Report
- Bridging the Alzheimer’s Translational Gap
- CAR Therapies for Autoimmune Diseases
- Cardiovascular Innovation: Precision Medicine and Cardiometabolic Convergence
- Cell Therapy 2024 Q3 Insight Pack
- China’s Rise in ADC Development Report
- Co-Stimulatory Bispecifics Report
- Cytokine Innovation in IBD Report
- Cytokine-Armoured Cell Therapies: Overcoming Immunosuppression and Improving Persistence
- Deals & Companies Report: Global Commercial Insights From The Biologics Market
- Degraders for Neurological Diseases
- Delving Deeper into Allergy Drug Development:
- Disease Trends in the Oligonucleotide Space
- Gene Therapies For Neurological Diseases
- Global Commercial Insights From the Bispecific and Multispecific Market
- In Vivo CAR Therapies: Review of a Novel Modality
- Inside China’s Innovation Engine: NMPA Approvals, Designations and Clinical Entry
- Investment Trends in Early Stage BioPharma
- Late-Stage Gene Therapy Development Report
- Monoclonal Antibodies (mAbs) Unveiled: A Comprehensive Review of the Landscape in Immune-Mediated Diseases
- MRD Market Insights & Trends
- Navigating the Complex Landscaspe of Skysona and Hematologic Cancer
- Obesity Drug Development Landscape
- Obesity Therapeutics: Emerging Technologies
- Oligonucleotides for Neurological Disorders
- Oncolytic Viruses: Monotherapies vs. Combination Therapy
- PD-(L)1/VEGF – Replacing the Backbone of Solid Tumor Oncology?
- PD-L1: An Endless Classic or Passing Fancy?
- Pre-Clinical Cytokine Drug Development: An Analysis of the Latest Data
- Review of RNA Clinical Research
- Rising East: Asia’s Expanding Influence in Global Autoimmune Innovation
- RNA 2024 Q4 Insight Pack
- RNA Therapeutics for CVRM Disorders
- Strategic Insights for Biopharma Innovation
- T Cell Engager Landscape Report
- The 2026 Colorectal Cancer Landscape Report
- The 2026 RAS Drug Development Landscape
- The Acceleration Of In Vivo CAR Therapies Report
- The Blood Cancer Landscape Report
- The Breast Cancer Landscape
- The CAR T Therapy In Asia Landscape Report
- The Checkpoint Disease Landscape: Exploring the Top Cancer Indications
- The Colorectal Cancer Landscape
- The Evolving Brain Cancer Landscape
- The KRAS Drug Development Landscape Report
- The Latest Breakthrough in Autoimmune Therapy
- The Multiple Sclerosis Drug Development Landscape Report
- The Neurology Drug Development Commercial Landscape
- The Oligonucleotide Landscape
- The Power of Precision: Exploring Editing Technologies in Gene Therapy
- The Rise of ADCs and Novel Drug Conjugates in Asia
- The State of T Cell Engagers in 2026
- The US Market and LBP Development
- TIGIT Axis Therapies and The Cancer Clinical Trial Landscape
- Treg Therapies in Autoimmune Diseases
- Trends and Challenges in Early-Stage Cytokine-Based Drug Development Commercialization
- VEGF PDL-1 Multispecifics Report
APIs
Data
Market Research
Blogs
- ADC Patents: Global Geographical Trends
- Application of Behavioral Economics to Life Science Market Research
- BIO 2026: The Trends Reshaping the Future of Biopharma
- Breaching The Fortress: The New Wave of Companies Cracking The Blood Brain Barrier
- Data Optimization: The Overlooked Layer in AI-Enabled Intelligence
- Dual Targeting: The Final Piece in the Blood Brain Barrier Puzzle?
- In Vivo CAR T Cell Therapies
- Market Intelligence for CDMOs: Turning Market Complexity into Commercial Growth
- Multispecific Antibodies: Focus on VEGF–PD-L1 Bispecific Agents
- The Future of Alzheimer’s Disease Drug Development
- The Illusion of Intelligence: Why Drug Developers Cannot Rely on AI for High Value Decisions
- Trial Data Harmonization
Demo Requests
- Beacon CVRM – Obesity Early Access Request
- Request a Beacon ADC Demonstration
- Request a Beacon Autoimmune Demonstration
- Request a Beacon Bispecific Demonstration
- Request a Beacon Cancer Vaccine Demonstration
- Request a Beacon Cell Therapy Demonstration
- Request a Beacon Checkpoint Demonstration
- Request a Beacon CVRM Demonstration
- Request a Beacon Cytokine Demonstration
- Request a Beacon DDR Demonstration
- Request a Beacon Gene Therapy Demonstration
- Request a Beacon Microbiome Demonstration
- Request a Beacon Neurology Demonstration
- Request a Beacon Neuroscience Demonstration
- Request a Beacon Oncology Demonstration
- Request a Beacon Oncolytic Viruses Demonstration
- Request a Beacon Patents Demonstration
- Request a Beacon Patents Demonstration – Beacon Customer
- Request a Beacon Psychiatric Demonstration
- Request a Beacon RNA Demonstration
- Request a Beacon TPD Demonstration
- Request a Demonstration
Citations
- Antibody-drug conjugates: Current challenges and innovative solutions for precision cancer therapy
- Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials
- Breaking the mold with RNA—a “RNAissance” of life science
- Enzymatic glycan remodeling–metal free click (GlycoConnect™) provides homogenous antibody-drug conjugates with improved stability and therapeutic index without sequence engineering
- Exploration of the antibody–drug conjugate clinical landscape
- First platinum(II)-based metal-organic linker technology (Lx®) for a plug-and-play development of antibody-drug conjugates (ADCs)
- Frameworks for transformational breakthroughs in RNA-based medicines
- Fundamental properties and principal areas of focus in antibody-drug conjugates formulation development
- Gene Editing Strategies for Neurological and Mental Disorders: Advances in Delivery, Methodology, and Clinical Translation
- Immunotherapy by mesenchymal stromal cell delivery of oncolytic viruses for treating metastatic tumors
- Impact of Maleimide Disubstitution on Chemical and Biological Characteristics of HER2 Antibody−Drug Conjugates
- Innovative antibody therapeutic development in China compared with the USA and Europe
- Modular generation of multispecific antibodies using protein trans-splicing
- Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates
- mRNA vaccines and therapeutics beyond COVID-19: A review of the global clinical development landscape, low- and middle-income countries involvement and relevance to their contexts
- Navigating Solid Tumor Heterogeneity: The Promise and Challenges of Antibody-Drug Conjugates
- Novel development strategies and challenges for anti-Her2 antibody-drug conjugates
- Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD)
- Present Scenario and Future Landscape of Payloads for ADCs: Focus on DNA-Interacting Agents
- Proximity-Based Modalities for Biology and Medicine
- Recent Highlights in the Discovery and Design of Antibody-Drug Conjugates
- Site-specific conjugation of native antibody
- Switchable assembly and function of antibody complexes in vivo using a small molecule
- The 17th EFMC Short Course on Medicinal Chemistry on Small Molecule Protein Degraders
- The complexities of oligonucleotide therapeutics: analytical challenges and opportunities within early drug discovery
- What makes a good antibody-drug conjugate?
Thought Leaderships
Videos
- News
Categories
- About Beacon
- Key Use Cases
FAQ Categories
- Consulting
- Database Solutions
Product Category
Search